Institut Jules Bordet — Clinical Trial Site

247 Registered trials

126 Currently recruiting

Organisation

Institut Jules Bordet

Location

Anderlecht, Belgium

Identifier

ORG-100006103

Address

Mijlenmeersstraat 90, 1070, Belgium

Departments

-
#1006: oncology
#2033: Hematology
#2052: Oncologie Médicale
001:Oncologie Médicale
032005:Oncologie Médicale
0501: Clinique d'Oncologie Médicale
0501: Oncologie
0505 Oncologie Médicale
1001:Nucleair Medicine
1108: Hematologie
1602: Hématologie
303: Hematologie
303: Oncologie Médicale
32004: Oncologie Médicale
Chemotherapy
Chirurgie gynécologique
Clinical Hematology
Clinical Trial Conduct Unit
Clinical Trial Conduct Unit (Completed) / Medicine Oncology (Incomplete)
Clinical Trials Conduct Unit
Clinique d'Oncologie Médicale
CTSU ATPT and Medical Oncology
Departement of Hematology
Department of Gastrointestinal Oncology
Department of Haematology
Department of Hematology
Department of Medical Oncology
Department of Oncology
Dept of gastroenterology/hepatopancreatology/digestive oncology
Dept of Medical Oncology
Dept. of Medical Oncology
Digestive Oncology
Gastro-enterology
Gastro-intestinal Medical Oncology
Gastroenterology
GastroIntestinal Medical Oncology
Gynecologic Oncology
Haematology
Hématologie
Hematology
Hematology department
Infectiology
Infectious disease
Infectious diseases
Institut Jules Bordet
Lung oncology
Medical Oncology
Medical Oncology - GI department
Medical Oncology / Clinical Trials Conduct Unit
Medical oncology department
MEDICAL ONCOLOGY/ HEAD OF CTCU
Medicine Oncology
Medische Oncologie
N/A
NA
Nucleaire geneeskunde
Nuclear medicine
Oncolgy
Oncologie
Oncologie digestive
Oncologie médicale
Oncology
Oncology department
PHU-Digestive Oncology Department
Pneumology
Radiation oncology
Radiotherapy
Radiotherapy-Oncology
Research, Medical oncology
Surgical Oncology
Thoracic Oncology
Thoracic Oncology Clinic
Treatment centre

Clinical trials at this site (247)

Search interface

A Study of Disitamab Vedotin Alone and with Pembrolizumab in Urothelial Cancer That Expresses HER2 Not authorised

2022-500030-28-00 Urothelial carcinoma 4
HER2 molecular imaging with 89Zr-trastuzumab PET/CT as a predictive biomarker for antibody-drug conjugate sequencing in patients with advanc… Not authorised

2024-516253-49-00 advanced/metastatic HER2-positive breast carcinoma 4
Single-arm, multicenter, phase II study of immunotherapy in patients with type B3 thymoma and thymic carcinoma previously treated with chemo… Pending

2023-508658-24-00 type B3 thymoma and thymic carcinoma 4
MInimal residual Disease Adapted Strategy / IFM 2020-02 Pending

2024-513889-19-00 Multiple Myeloma 5
A Phase Ib/II Open-Label, Multicentre Platform Study Evaluating Novel Combinations in Participants with Advanced or Metastatic Non-Small Cel… Pending

2024-519786-22-01 metastatic non-small cell lung cancer (NSCLC) 9
A phase 1/2a, first-in-human, open-label, dose-escalating study with a safety expansion cohort to evaluate safety, tolerability, pharmacokin… Pending

2025-521164-36-00 Patients with relapsed/refractory advanced/metastatic o 7
A Study Testing the Investigational Drug XmAb541 in people with Advanced Cancer Pending

2025-521981-90-00 Advanced Solid Tumors 1
Phase 3 Study of INCB123667 Versus Investigator's Choice of Chemotherapy in Platinum Resistant Ovarian Cancer With Cyclin E1 Overexpression Pending

2025-522748-42-00 Ovarian cancer 5
Phase II study of ezabenlimab in patients with PD-L1-positive head and neck cancer with residual disease detected by ctDNA after chemoradiot… Pending

2025-523575-36-00 Locally advanced head and neck squamous cell carcinoma 4
A Research Study Testing New Cancer Medicines Used Alone or Together to Treat Solid Tumors Pending

2025-524623-50-00 Solid Tumors 9
A Randomized, Double-Blind, Phase 3 Study of Chemotherapy With or Without INCB161734 in Previously Untreated, KRAS G12D–Mutated Metastatic P… Pending

2025-525009-18-00 Pancreatic Ductal Adenocarcinoma 5
A study to Assess Intravenous (IV) Telisotuzumab Adizutecan in Combination with IV Bevacizumab Compared to Standard of Care IV Bevacizumab i… Recruiting

2025-521712-19-00 Colorectal Cancer 5 2026-07-06
A Study of Pumitamig Versus Durvalumab Following Concurrent Chemoradiation Therapy in Participants with Unresectable Stage III NSCLC Recruiting

2025-523576-23-00 Unresectable Stage III non-small cell lung cancer witho 5 2026-06-12
A Two-Part Phase 3 Study of Sofetabart Mipitecan (LY4170156) in Participants with Platinum-Resistant (Part A) and Platinum-Sensitive (Part B… Recruiting

2025-522255-25-00 Fallopian Tube Neoplasms 5 2026-05-18
A Clinical Trial to Compare the Effectiveness and Safety of RO7771950 in Combination with Trastuzumab and Capecitabine, Versus Tucatinib in … Recruiting

2025-524498-17-00 Pretreated Unresectable Locally Advanced or Metastatic 10 2026-05-08
A clinical study of sacituzumab tirumotecan in people with ovarian cancer (MK-2870-021) Recruiting

2023-508047-40-00 Ovarian cancer 5 2026-04-30
Evaluating a Personalized Treatment Strategy for Young Women with Early Breast Cancer Recruiting

2024-519655-28-00 Premenopausal patients with high-risk HR-positive/HER2- 5 2026-04-23
A Study to assess the Safety, Tolerability and effect of RO7673396 when used alone as well as with other cancer medications in participants … Recruiting

2024-519622-20-00 Advanced Solid Tumors Harboring RAS Mutation(S) 1 2026-02-27
A Global Phase III Study of Puxitatug Samrotecan (AZD8205) Monotherapy Compared with Physician’s Choice of Chemotherapy for B7-H4-Selected E… Recruiting

2024-518777-34-00 B7-H4-Selected Advanced/Metastatic Endometrial Cancer. 5 2026-02-11
Testosterone intake in supportive care patients: impact on quality of life. Recruiting

2025-522023-10-00 Androgen deficiency, palliative care 4 2026-02-11
A study to investigate the effect of adding bleximenib to standard-of-care treatment with intensive chemotherapy in patients with a specific… Recruiting

2025-522767-15-00 Acute Myeloid Leukemia 5 2026-01-27
A clinical study of sacituzumab tirumotecan for cervical cancer (MK-2870-036) Recruiting

2025-521514-26-00 Persistent, Recurrent, or Newly Diagnosed Metastatic Ce 5 2026-01-26
LuMIERE: A Phase 1/2, Multicenter, Open label, Non randomized Study to Investigate Safety and Tolerability, Pharmacokinetics, Dosimetry, and… Recruiting

2023-508995-12-01 Recurrent or metastatic non-small cell lung cancer (NSC 4 2025-12-24
A clinical study of the anti-cancer effects of an investigational therapy or chemotherapy in patients with recurring uterine cancer Recruiting

2023-507525-42-00 Endometrial cancer 5 2025-12-23